17427-37-1

Basic information

• Product Name: 1-(2-ISOTHIOCYANATO-ETHYL)-4-METHOXY-BENZENE
• Synonyms: 1-(2-isothiocyanatoethyl)-4-methoxybenzene(SALTDATA: FREE);1-(2-Isothiocyanatoethyl)-4-methoxybenzene AldrichCPR
• CAS NO: 17427-37-1
• Molecular Formula: C₁₀H₁₁NOS
• Molecular Weight: 193.27
• Mol File: 17427-37-1.mol

Chemical Properties

• Boiling Point: 323 °C at 760 mmHg
• Flash Point: 149.2 °C
• Appearance: /
• Density: 1.05 g/cm³
• Vapor Pressure: 0.000508mmHg at 25°C
• Refractive Index: 1.539
• CAS DataBase Reference: 1-(2-ISOTHIOCYANATO-ETHYL)-4-METHOXY-BENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-ISOTHIOCYANATO-ETHYL)-4-METHOXY-BENZENE(17427-37-1)
• EPA Substance Registry System: 1-(2-ISOTHIOCYANATO-ETHYL)-4-METHOXY-BENZENE(17427-37-1)

Safety Data

• Statements: 43
• Safety Statements: 36/37
• Hazardous Substances Data: 17427-37-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(2-ISOTHIOCYANATO-ETHYL)-4-METHOXY-BENZENE is used as a pharmaceutical agent for its potential anticancer properties. It may contribute to the development of new drugs targeting various types of cancer due to its biological activities.
Used in Agriculture:
In the agricultural industry, 1-(2-ISOTHIOCYANATO-ETHYL)-4-METHOXY-BENZENE is used as an insect repellant and in pest control formulations. Its potential role in these applications can help protect crops from harmful insects and pests, thereby increasing agricultural productivity.
Used in Biotechnology:
1-(2-ISOTHIOCYANATO-ETHYL)-4-METHOXY-BENZENE is utilized in biotechnology for its antimicrobial properties. It can be employed in the development of new antimicrobial agents to combat various microbial infections, contributing to advancements in healthcare and disease prevention.

InChI:InChI=1/C10H11NOS/c1-12-10-4-2-9(3-5-10)6-7-11-8-13/h2-5H,6-7H2,1H3

Upstream product

• 463-71-8 thiophosgene 
• 55-81-2 4-Methoxyphenethylamine 
• 6160-65-2 1,1'-Thiocarbonyldiimidazole 

Downstream Products

• 143543-81-1 (4,5-Dihydro-thiazol-2-yl)-[2-(4-methoxy-phenyl)-ethyl]-amine 

Relevant articles and documents

Synthesis and SAR of novel capsazepine analogs with significant anti-cancer effects in multiple cancer types

We previously demonstrated that capsazepine (CPZ), a synthetic transient receptor potential Vanilloid subtype 1 (TRPV1) antagonist, has significant anti-cancer effects in vivo. The purpose of this study was to develop more potent analogs based upon CPZ pharmacophore and structure–activity relationships (SAR) across analogs. We generated 30 novel compounds and screened for their anti-proliferative effects in cultured HeLa cervical cancer cells. Cell viability assays identified multiple compounds with IC50s 50 50s of 1–2.5 μM in HSC-3and PC-3cells. Thus, we propose that these novel CPZ analogs may serve as efficacious therapeutic agents against multiple tumor types that warrant further development for clinical application.

The role of 5-arylalkylamino- and 5-piperazino- moieties on the 7-aminopyrazolo[4,3-d]pyrimidine core in affecting adenosine A1 and A2A receptor affinity and selectivity profiles

New 7-amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives, substituted at the 5-position with aryl(alkyl)amino- and 4-substituted-piperazin-1-yl- moieties, were synthesized with the aim of targeting human (h) adenosine A1 and/or A2A receptor subtypes. On the whole, the novel derivatives 1–24 shared scarce or no affinities for the off-target hA2B and hA3 ARs. The 5-(4-hydroxyphenethylamino)- derivative 12 showed both good affinity (Ki = 150 nM) and the best selectivity for the hA2A AR while the 5-benzylamino-substituted 5 displayed the best combined hA2A (Ki = 123 nM) and A1 AR affinity (Ki = 25 nM). The 5-phenethylamino moiety (compound 6) achieved nanomolar affinity (Ki = 11 nM) and good selectivity for the hA1 AR. The 5-(N4-substituted-piperazin-1-yl) derivatives 15–24 bind the hA1 AR subtype with affinities falling in the high nanomolar range. A structure-based molecular modeling study was conducted to rationalize the experimental binding data from a molecular point of view using both molecular docking studies and Interaction Energy Fingerprints (IEFs) analysis. (Figure presented.).

Bronchorelaxing compounds

A compound of the general formula (I) including its pharmaceutically acceptable acid addition salts wherein A is CHR9, wherein R9 is H, C1-C6 alkyl; n is 1-3; B is CHR10, wherein R10 is H, C1-C6 alkyl; m is 1 or 2; D is O or S or optionally NR16, wherein R16 is H, C1-C6 alkyl or C2-C6 acyl; E is CR11R12 or NR13, wherein R11 and R12 are, independent of each other, H or C1-C6 alkyl, R13 is H or C1-C6 alkyl; F is C1-C18 alkyl which may be mono- or di-unsaturated and/or substituted, is useful in treating and preventing pulmonary disease characterized by bronchoconstriction. Also disclosed are pharmaceutical compositions comprising the compound and methods for their manufacture.

Synthesis and Octopaminergic Agonist Activity of 2-(Substituted benzylamino)-2-thiazolines

2-(Substituted benzylamino)-2-thiazolines (SBAT) were synthesized by a hydrochloric acid-catalyzed cyclization of the corresponding thioureas, using a reaction of 2-methylthio-2-thiazoline with substituted benzylamines or by alkylating 2-amino-2-thiazoline. 2-(Alkylthio)-2-thiazolines were obtained by alkylating 2-mercaptothiazoline.Most of the SBAT compounds activated adenylate cyclase in homogenates of cockroach ventral nerve cords; the effect of introducing substituents at the phenyl of the SBAT compounds on octopaminergic agonist activity was not significant. 2--2-thiazolines and 2-(alkylthio)-2-thiazolines were not significant octopaminergic agonists.Washing removed nearly all of the activity of one of the SBAT compounds, suggesting that the SBAT compounds bound reversibly to the octopaminergic receptor.